Loading
Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.
Andrew Tutt is Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden and Guy's. His specialisms are triple-negative breast cancer, BRCA and DNA repair, PARP inhibitors and platinum chemotherapy. His work on BRCA-deficient breast cancer runs from the first clinical proof-of-concept for a PARP inhibitor, through the TNT trial of carboplatin in BRCA1/2-mutated and triple-negative subgroups reported in Nature Medicine, to OlympiA, the adjuvant olaparib trial in BRCA-mutated breast cancer published in the New England Journal of Medicine. This body of work defined DNA-repair-targeted therapy in breast cancer. His ICR profile and PubMed listing are linked.
Answers the two questions that hung over adjuvant olaparib, durability and late leukaemia, in its favour; the remaining question is whether carriers who also received pembrolizumab or capecitabine, whom the trial did not study, get the same benefit.
The survival result that moved adjuvant olaparib from a disease-free survival approval to an undisputed standard, and the reason germline testing at diagnosis of triple-negative breast cancer is now a treatment decision rather than a family history exercise.
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
One pairing page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial, Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, OlympiA.
Shares Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, OlympiA, PARP.
Shares Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents.
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares TNT (Triple Negative Trial), PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD).
Shares Jean Abraham, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial, OlympiA, Olaparib, BRCA1 / BRCA2 (HRD).